Casi Pharmaceuticals Stock Market Value
| CASI Stock | USD 1.48 0.06 4.23% |
| Symbol | CASI |
CASI Pharmaceuticals Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CASI Pharmaceuticals. If investors know CASI will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CASI Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.54) | Revenue Per Share | Quarterly Revenue Growth 0.83 | Return On Assets | Return On Equity |
The market value of CASI Pharmaceuticals is measured differently than its book value, which is the value of CASI that is recorded on the company's balance sheet. Investors also form their own opinion of CASI Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is CASI Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CASI Pharmaceuticals' market value can be influenced by many factors that don't directly affect CASI Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CASI Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if CASI Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CASI Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
CASI Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to CASI Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of CASI Pharmaceuticals.
| 04/27/2025 |
| 07/26/2025 |
If you would invest 0.00 in CASI Pharmaceuticals on April 27, 2025 and sell it all today you would earn a total of 0.00 from holding CASI Pharmaceuticals or generate 0.0% return on investment in CASI Pharmaceuticals over 90 days. CASI Pharmaceuticals is related to or competes with Annexon, Cidara Therapeutics, Cellectar Biosciences, Cyclerion Therapeutics, ESSA Pharma, Gyre Therapeutics, and Tempest Therapeutics. CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical pro... More
CASI Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure CASI Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess CASI Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.09) | |||
| Maximum Drawdown | 41.17 | |||
| Value At Risk | (7.52) | |||
| Potential Upside | 9.76 |
CASI Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for CASI Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as CASI Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use CASI Pharmaceuticals historical prices to predict the future CASI Pharmaceuticals' volatility.| Risk Adjusted Performance | (0.03) | |||
| Jensen Alpha | (0.36) | |||
| Total Risk Alpha | (1.87) | |||
| Treynor Ratio | (1.12) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of CASI Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
CASI Pharmaceuticals Backtested Returns
CASI Pharmaceuticals secures Sharpe Ratio (or Efficiency) of -0.0633, which signifies that the company had a -0.0633 % return per unit of volatility over the last 3 months. CASI Pharmaceuticals exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm CASI Pharmaceuticals' Market Risk Adjusted Performance of (1.11), mean deviation of 3.57, and Variance of 31.65 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 0.27, which signifies not very significant fluctuations relative to the market. As returns on the market increase, CASI Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding CASI Pharmaceuticals is expected to be smaller as well. At this point, CASI Pharmaceuticals has a negative expected return of -0.36%. Please make sure to confirm CASI Pharmaceuticals' skewness, as well as the relationship between the rate of daily change and price action indicator , to decide if CASI Pharmaceuticals performance from the past will be repeated in the future.
Auto-correlation | 0.55 |
Modest predictability
CASI Pharmaceuticals has modest predictability. Overlapping area represents the amount of predictability between CASI Pharmaceuticals time series from 27th of April 2025 to 11th of June 2025 and 11th of June 2025 to 26th of July 2025. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of CASI Pharmaceuticals price movement. The serial correlation of 0.55 indicates that about 55.0% of current CASI Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.55 | |
| Spearman Rank Test | 0.13 | |
| Residual Average | 0.0 | |
| Price Variance | 0.03 |
CASI Pharmaceuticals lagged returns against current returns
Autocorrelation, which is CASI Pharmaceuticals stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting CASI Pharmaceuticals' stock expected returns. We can calculate the autocorrelation of CASI Pharmaceuticals returns to help us make a trade decision. For example, suppose you find that CASI Pharmaceuticals has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
CASI Pharmaceuticals regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If CASI Pharmaceuticals stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if CASI Pharmaceuticals stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in CASI Pharmaceuticals stock over time.
Current vs Lagged Prices |
| Timeline |
CASI Pharmaceuticals Lagged Returns
When evaluating CASI Pharmaceuticals' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of CASI Pharmaceuticals stock have on its future price. CASI Pharmaceuticals autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, CASI Pharmaceuticals autocorrelation shows the relationship between CASI Pharmaceuticals stock current value and its past values and can show if there is a momentum factor associated with investing in CASI Pharmaceuticals.
Regressed Prices |
| Timeline |
Currently Active Assets on Macroaxis
| USOI | Credit Suisse X Links | |
| ULTY | Tidal Trust II | |
| CONY | YieldMax N Option | |
| BCAT | BlackRock Capital Allocation | |
| PDI | Pimco Dynamic Income |
Check out CASI Pharmaceuticals Correlation, CASI Pharmaceuticals Volatility and CASI Pharmaceuticals Alpha and Beta module to complement your research on CASI Pharmaceuticals. For more detail on how to invest in CASI Stock please use our How to Invest in CASI Pharmaceuticals guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
CASI Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.